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Abstract 24 
Non-ionic surfactant vesicles (NISV) are synthetic membrane vesicles formed by self-25 
assembly of a non-ionic surfactant, often in a mixture with cholesterol and a charged 26 
chemical species. Different methods can be used to manufacture NISV, with the majority 27 
of these requiring bulk mixing of two phases. This mixing process is time-consuming and 28 
leads to the preparation of large and highly dispersed vesicles, which affects the 29 
consistency of the final product and could hinder subsequent regulatory approval. In this 30 
study, we have compared the physical characteristics of NISV prepared using two 31 
conventional methods (thin-film hydration method and heating method) with a recently 32 
introduced microfluidic method. The resulting particles from these methods were assessed 33 
for their physical characteristics and in vitro cytotoxicity. Through microfluidics, nano-34 
sized NISV were prepared in seconds, through rapid and controlled mixing of two miscible 35 
phases (lipids dissolved in alcohol and an aqueous medium) in a microchannel, without the 36 
need of a size reduction step, as required for the conventional methods. Stability studies 37 
over two months showed the particles were stable regardless of the method of preparation 38 
and there were no differences in terms of EC50 on A375 and A2780 cell lines. However, 39 
this work demonstrates the flexibility and ease of applying lab-on-chip microfluidics for 40 
the preparation of NISV that could be used to significantly improve formulation research 41 
and development, by enabling the rapid manufacture of a consistent end-product, under 42 
controlled conditions. 43 
Key words: Non-ionic surfactant vesicles, microfluidics, thin-film hydration, heating 44 
method, drug delivery, cytotoxicity. 45 
 46 
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1. Introduction 47 
Non-ionic surfactant vesicles (NISV) or ³niosomes´, are synthetic bilayer vesicles 48 
typically formed by the self-assembly of non-ionic surfactants [1], cholesterol and the 49 
addition of a charged species. The self-assembly of non-ionic surfactants into bilayer 50 
vesicles, first reported in the 1980s by a group of cosmetic researchers from /¶2UpDO 51 
industries [2], have since been applied extensively as drug delivery systems. NISV exhibit 52 
more advantages over liposomes, in terms of cost and stability, and constituent surfactants 53 
have a wider range of chemistries that can be selected to provide greater potential for 54 
innovation related to vesicle composition [1, 3]. Surfactants commonly employed include 55 
polyoxyethylene fatty acid esters (Tweens), sorbitan fatty acid esters (Spans), alkyl ethers, 56 
and alkyl glyceryl ethers (Brijs) [4], while other additives include cholesterol, which affects 57 
the mechanical strength and permeability of the bilayer structure [5, 6], and charged 58 
molecules such as dicetyl phosphate (negative) and stearylamine (positive) [3], which 59 
prevent particle aggregation through electrostatic repulsion mechanisms.  60 
NISV have been used to deliver hydrophilic drugs that are encapsulated in the interior 61 
aqueous compartment or adsorbed on the bilayer surface, and hydrophobic drugs that are 62 
localised within the lipid bilayer of the NISV [7]. NISV have also been used to improve 63 
solubility and subsequently bioavailability of poorly soluble drugs, as exemplified by 64 
aciclovir and griseofulvin [8, 9]. Moreover, these particles can also improve the stability 65 
of peptide drugs, e.g. they have been shown to protect encapsulated insulin in the 66 
gastrointestinal tract from degradation by proteolytic enzymes and exhibit good stability in 67 
the presence of bile acid salts such as sodium deoxycholate [10]. Other applications of 68 
NISV have been in the area of transdermal delivery of different drugs such as oestradiol, 69 
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enoxacin and minoxidil [11-13] and in gene delivery of topical DNA vaccines [14, 15]. In 70 
recent years, NISV have also been used as carriers for contrast agents for clinical imaging 71 
applications in medical diagnostic tools [16]. 72 
Various conventional bulk methods have been used in the preparation of NISV (e.g. thin-73 
film hydration, reversed phase evaporation, and heating methods), which utilise mixing of 74 
two liquid phases on a bench scale at elevated temperature, in order to facilitate 75 
spontaneous self-assembly of the lipid components into bilayer vesicles [1, 17, 18]. The 76 
hydration of a thin lipid film (Bangham method) is a simple and widely used process, in 77 
which a mixture of lipids are dispersed in an organic solvent (such as chloroform) followed 78 
by evaporation of the solvent using a rotary evaporator to form a dry lipid film on the flask 79 
wall. NISV are then spontaneously self-assembled by hydrating the lipid film with an 80 
aqueous buffer at a temperature above the phase transition temperature of lipids [19]. 81 
Hydrophilic drugs can be encapsulated in the formed vesicles by adding the drug in the 82 
aqueous buffer when hydrating the lipid film, while hydrophobic drugs can be dissolved 83 
with the lipid components before forming the lipid film [20]. Another method reported by 84 
Mozafari et al. is the heating method [21], in which NISV can be prepared without the use 85 
of organic solvents, where the various components are hydrated in aqueous media at room 86 
temperature followed by heating at 120°C with mechanical stirring [22]. However, the 87 
methods described above, result in the production of large particles, with high 88 
polydispersity, as a result of inadequate control of chemical and mechanical environments. 89 
These methods necessitate the use of post-production size-altering steps, such as extrusion 90 
or sonication, in order to obtain smaller and more homogeneous vesicle dispersions [1, 18]. 91 
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The ability to control vesicle size and polydispersity is a crucial factor in the success of 92 
any manufacturing method as the particle size of the delivery system influences in vivo 93 
performance [23]. Microfluidic mixing is a recently developed method used to prepare 94 
liposomes, which results in the production of small vesicles with efficient encapsulation of 95 
a therapeutic agent [24]. In microfluidics, lipids are dissolved in an organic phase and the 96 
aqueous phase is introduced from different inlets into a precisely defined microchannel that 97 
allows for fast mixing between the two phases at high flow rates and at a temperature above 98 
the phase transition of the lipids. By controlling flow rate ratios (FRR) between the aqueous 99 
and organic phase and total flow rates (TFR) of both phases, homogeneous small vesicles 100 
can be prepared in a single step [23, 25].  101 
The main objective of this work was to compare the characteristics of NISV prepared by 102 
these different manufacturing methods. Previous work from our lab has successfully 103 
investigated the development of NISV for vaccine delivery composed of monopalmitin 104 
glycerol (MPG), cholesterol (Chol) and dicetyl phosphate (DCP) at a molar ratio of 5:4:1 105 
of MPG:Chol:DCP [26] so this was used to prepare the NISV. Moreover, in previous work, 106 
we have demonstrated that the type of the aqueous media can significantly affect vesicle 107 
characteristics prepared by microfluidics [27], so we chose phosphate buffered saline 108 
(PBS) to prepare the NISV in all the methods of preparation. The prepared particles were 109 
then compared for their physical characteristics, stability over time and in vitro 110 
cytotoxicity.  111 
 112 
 113 
 114 
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Materials and methods 115 
2.1. Materials 116 
MPG was purchased from Larodan Fine Chemicals AB (Sweden).  Chol, DCP, PBS tablets, 117 
resazurin powder, serum-free and antibiotic-free Roswell Park Memorial Institute medium 118 
(RPMI 1640), L-glutamine, penicillin±streptomycin, and foetal bovine serum (FBS) were 119 
purchased from Sigma±Aldrich (UK) (all at cell culture grade). The human cell lines skin 120 
malignant melanoma (A375) and ovarian carcinoma (A2780) were purchased from the 121 
American Type Culture Collection (ATCC®). 122 
2.2. Preparation of NISV by the thin-film hydration (TFH) method 123 
NISV were prepared using the thin-film hydration (TFH) method as described elsewhere 124 
[28]. Briefly, MPG, Chol and DCP were mixed at a molar ratio of 5:4:1 with a total weight 125 
of 22.5 mg (MPG: 9.96mg, Chol: 9.27mg, DCP: 3.27mg). The mixture was placed in a 126 
round bottomed flask and dissolved in 9 ml chloroform. Chloroform was then evaporated 127 
using a rotary evaporator (Rotavapor R-3, BTECH, Switzerland) operated at 50rpm under 128 
vacuum at 50°C until complete solvent evaporation and a thin lipid film formed on the 129 
flask wall. The thin-film was hydrated with 9 ml of PBS (pH 7.4) at 50°C by rotating the 130 
flask at 50 rpm until the lipid film was completely hydrated and a milky suspension was 131 
formed with a final concentration of 2.5 mg/ml.  132 
2.3. Preparation of NISV by the heating method 133 
NISV were prepared by the heating method as described elsewhere with modifications 134 
[22]. Briefly, MPG, Chol and DCP at a molar ratio of 5:4:1 were hydrated at room 135 
temperature with PBS (10 mM, pH 7.4). The mixture was then heated to 140°C with 136 
continuous stirring for two min to form the NISV with a final concentration of 2.5 mg/ml.  137 
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2.4. NISV particle size reduction 138 
NISV suspensions prepared by the TFH and heating methods were manually extruded 21 139 
times using an Avanti miniextruder containing a 100 nm pore diameter polycarbonate (PC) 140 
membrane (Avanti polar lipids, Alabaster, AL, USA) at 50°C to reduce the particle size 141 
and distribution.  142 
2.5. Preparation of NISV by microfluidics 143 
NISV were prepared using a NanoAssemblrTM (Benchtop, Precision NanoSystems Inc., 144 
Vancouver, Canada) as described by Obeid et al. [27]. The mixing of the two phases 145 
allowed formation of controlled sized NISV [29]. To prepare NISV at a final concentration 146 
of 2.5 mg/ml, MPG, Chol and DCP were dissolved in ethanol to prepare a stock solution 147 
of 20 mg/ml for each of the components. Specific volumes from each stock solution were 148 
mixed together to prepare the lipid phase of MPG, Chol and DCP in a molar ratio of 5:4:1. 149 
The lipid phase was injected into the first inlet and the aqueous phase into the second inlet 150 
of the microfluidic micromixer, with the mixing temperature set at 50°C. The FRR of 151 
aqueous phase to lipid phase was set at 3:1 and the TFR was set at 12 ml/min. Dispersions 152 
were collected from the outlet stream and immediately diluted with PBS in order to reduce 153 
the final ethanol content in the preparation to 6.25% (v/v).  154 
2.6 Particle size, polydispersity and charge of NISV 155 
Particle size, poly dispersity index (PDI) and Zeta potential (ZP) were measured with a 156 
Zetasizer Nano-ZS (Malvern Instruments, UK). The measurements were performed for 157 
NISV prepared by each method at 25°C at a 1 in 20 dilution in PBS. All samples were 158 
prepared in triplicate and the ZAverage, PDI, and ZP reported. 159 
 160 
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2.7 Stability studies of NISV prepared by different methods 161 
NISV prepared by all methods were tested for their stability over a two month period at 162 
either 4, 25, 37 or 50°C storage in controlled temperature rooms. Size, PDI, and ZP were 163 
measured at 0, 10, 20, 30, 40, 50, and 60 days. 164 
2.8 Morphological analysis of NISV using atomic force microscopy (AFM)  165 
Morphological examination of the NISV was performed by atomic force microscopy 166 
(AFM). Five µL of each formulation was deposited onto freshly cleaved mica surfaces 167 
(G250-2 Mica sheets 1" x 1" x 0.006"; Agar Scientific Ltd., Essex, UK), and air dried for 168 
~1 h before AFM imaging. The images were obtained by scanning the mica surface in air 169 
under ambient conditions using a Dimension FastScan BioAFM (Bruker, CA, USA) 170 
operated on Peak Force QNM mode. The AFM measurements were obtained using 171 
ScanAsyst-air probes; the spring constant was calibrated by thermal tune (0.52 N m-1; 172 
Nominal 0.4 N m-1) and the deflection sensitivity calibrated using a silica wafer. AFM 173 
images were collected by random spot surface sampling (at least three areas). The 174 
analyses were performed using the Nanoscope Analysis v1.4 (Bruker, USA). 175 
2.9  In vitro cytotoxicity studies 176 
 NISV were assessed for cytotoxicity on two different cell lines (A375 and A2780). Each 177 
cell line was seeded in a 96-well plate at a density of 1×104 per well in RPMI 1640 medium 178 
supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) penicillin-179 
streptomycin and incubated at 37 °C, 5 % CO2 and 100% humidity for 24 h. The cells were 180 
treated with a range of concentrations of NISV (9.77-1250 µg/ml) prepared by each 181 
method. Dimethyl sulphoxide (DMSO) was used as a positive kill control and one column 182 
per plate contained untreated cells and medium. PBS alone without the particles was also 183 
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included to ensure that the media itself used to prepare the particles was not toxic. The 184 
plates were then incubated for 24h and then treated with 20 ȝ/ of resazurin (0.1 mg/ml) to 185 
each well and incubated for a further 24 h. The transformation of resazurin into resorufin 186 
by the live cells was then detected by measuring the absorbance at 560 ± 590 nm using a 187 
SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA). The cell viability 188 
was calculated as a percentage of the absorbance from the treated cells with NISV to the 189 
absorbance of the untreated cells. 190 
2.10 The effects of TFR and FRR on NISV prepared by microfluidics 191 
The effects of TFT and TFR on the characteristics of the NISV prepared by microfluidics 192 
were also investigated. The TFR of aqueous buffer and lipid phase was varied from 0.5 193 
ml/min to 12 ml/min and the FRR of the aqueous to lipid phases was varied from 1:1 to 194 
5:1 and the particle size, charge and PDI measured. 195 
2.11 Statistical analysis 196 
All experiments were performed in triplicate and one way analysis of variance (ANOVA) 197 
was used to assess statistical significance. 7XNH\¶VPXOWLSOHFRPSDULsons test and a t-test 198 
were performed for paired comparisons. The statistical analysis was performed using 199 
Minitab software version 17. A value of p< 0.05 was considered to be statistically 200 
significant. Graphs were produced using OriginPro 2015. 201 
 202 
 203 
 204 
 205 
 206 
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3. Results  207 
3.1 The effect of the manufacturing method on the particles size, PDI and ZP 208 
Table 1 shows the characteristics of NISV, prepared by the TFH and heating methods 209 
(before and after extrusion) and those prepared by microfluidics. 210 
Dynamic light scattering revealed that the particle size of the extruded NISV prepared by 211 
the TFH method and heating method were small and monodisperse (124.7 ± 0.72 nm and 212 
152.34 ± 1.76 nm, respectively) while the non-extruded particles were large and 213 
polydisperse (Table 1). However, particles prepared by microfluidic mixing were small 214 
with a narrow particle distribution (165.90 ± 0.92 nm). Microfluidics can prepare small 215 
and monodisperse particles in minutes. However, the preparation of these particles with 216 
the other methods took hours to get the same results of microfluidics. The PDI values of 217 
the extruded NISV prepared by the TFH and heating methods were low (0.12 ± 0.01 and 218 
0.10 ± 0.02 respectivly) and comparable to the PDI value of the particles prepared by 219 
microfluidics (0.08 ± 0.02) with no significant difference (p>0.05). Moreover, since all the 220 
particles prepared by the three methods used the same lipid compositions, the ZP values 221 
for the extruded particles prepared by the TFH and the heating methods and by 222 
microfluidics were the same with no significiant difference (p>0.05) (Table 1). 223 
 224 
 225 
 226 
 227 
 228 
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Table 1. Comparison of particle characteristics prepared by the TFH method, heating 229 
method, and microfluidic mixing in terms of size, PDI and ZP. n=3 ± SD 230 
Method of preparation Size (nm) PDI ZP (mV) 
TFH (before extrusion) 1027.17 ± 75.79 0.83 ± 0.03 -12.30 ± 3.22 
TFH (after extrusion) 124.70 ± 0.72 0.12 ± 0.01 -28.70 ± 1.39 
Heating method (before extrusion) 3938.00 ± 95.25 0.85 ± 0.04 -14.50 ± 1.25 
Heating method (after extrusion) 152.34 ± 1.76 0.10 ± 0.02 -36.67 ± 3.14 
Microfluidic mixing 165.90 ± 0.92 0.08 ± 0.02 -31.38 ± 1.80 
 231 
3.2. The effects of the manufacturing method on overall NISV stability 232 
Figure 1 shows the stability in term of particles size of the NISV prepared by the three 233 
methods when stored at four different temperatures over two months. Samples were 234 
characterised immediately after preparations and again at each time point. The method of 235 
preparation was shown to have no effects on the particles stability as the particles prepared 236 
by the three methods exhibited nearly identical size distribution as the original samples at 237 
all the tested temperatures. 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
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 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
Figure 1. Size of NISV prepared by the TFH method, heating method, and microfluidic mixing and 
stored over 60 days at 4°C, 25°C, 37°C and 50°C. The data represents the mean ± SD (n=3).  
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3.3. Morphological analysis of NISV prepared by different methods 269 
Figure 2 shows the morphology of NISV prepared by the TFH and heating methods after 270 
extrusion and by microfluidics. All the particles were spherical in shape regardless of the 271 
method of preparation. Some images showed large particle aggregates, which are due to 272 
the high concentration of these particles in the tested samples which formed upon drying 273 
the sample on the mica surface. 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
 289 
 290 
3.4. Cytotoxicity study of NISV prepared by different methods 291 
A B 
Figure 2, AFM images for the NISV 
prepared by the (A) TFH method post 
extrusion, (B) heating method post 
extrusion, and (C) microfluidic mixing. 
C 
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Figure 3 shows the cytotoxicity of the NISV prepared by the three methods on A375 and 292 
A2780 cell lines and Table 2 shows the calculated EC50. All three formulations show the 293 
same cytotoxicity profile as the difference in the EC50 between the particles on both cell 294 
lines was not significant (p>0.05). 1,69ZLWKDFRQFHQWUDWLRQµg/ml found to be 295 
non-toxic where 100 % cell viability was detected on both cell lines regardless of the 296 
method of manufacturing. The buffer alone used in the vesicle preparation was not toxic 297 
and the cells were 100% viable (data not shown). 298 
 299 
 300 
 301 
 302 
 303 
 304 
Figure 3. Cytotoxicity of the NISV prepared by three methods on A375 and A2780 cell lines. The 
data represents the mean ± SD (n=3).  
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Table 2. EC50 values in (µg/ml) of NISV, prepared using three different manufacturing 305 
methods, on A375 and A2780 cells. The data represents the mean ± SD (n=3).  306 
 
Method of preparation 
(&ȝJPO 
A375 cell line A2780 cell line 
TFH method 254.7 ± 11.5 229.9 ± 14.43 
Heating method 258.9 ± 19.53 224.6 ± 28.32 
Microfluidic mixing 240.1 ± 13.81 228.9 ± 5.651 
 307 
3.5. The effects of TFR and FRR on NISV prepared by microfluidics 308 
Figure 4 shows the changes of the particles size by changing the FRR from 1:1 to 5:1 309 
(aqueous: lipid phases) and the TFR from 0.5-12 ml/min. As can be seen in Figure 4, as 310 
the aqueous/ethanol FRR increased from 1:1 to 5:1, a significant (p<0.05) reduction in 311 
NISV size was observed and found to be TFR dependant. At a TFR < 3 ml/min, the 312 
difference between the particles prepared at FRR of 3:1 and 5:1 was not significant 313 
(p>0.05). However, at higher TFR (> 3 ml/min), the difference between these two FRRs 314 
was significant (p<0.05). For example, at a TFR of 0.5 ml/min, the particle size prepared 315 
at FRR of 1:1, 3:1 and 5:1 were 219.71 ± 15.69 nm, 181.14 ± 6.65 nm, and 183.32 ± 4.88 316 
nm, respectively while at a TFR of 12 ml/min, the particle size for NISV was 177.73 ± 5.26 317 
nm at FRR 1:1, 165.90 ± 0.92 at FRR 3:1 and particles prepared at FRR 5:1 was 145.25 ± 318 
4.64 nm. The TFR was shown to have a significant (p<0.05) effect on particle size where 319 
the increase in the TFR from 0.5 ml/min to 9 ml/min resulted in an overall reduction in 320 
particle size at all the FRR. However, further increase in the TFR above 9 ml/min was not 321 
associated with a significant decrease in particle size at all the FRR (Figure 4). 322 
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Regarding the effects of the FRR on the total particle charge, the increase in the solvent 323 
concentration at lower FRR (1:1) results in a higher percentage of the charged material (i.e. 324 
DCP) in the particles. Therefore, as the FRR increased from 1:1 to 5:1 there was a decrease 325 
in the absolute value of the ZP from about -30 mV at 1:1 to about ± 20mV at 5:1 regardless 326 
of the TFR. This means that the FRR factor also has an effect on the ZP in addition to its 327 
effect on particle size. However, this effect on the ZP was not significant (p>0.05).  328 
 329 
 330 
 331 
Figure 4. Size changes of NISV prepared at different TFR and FRR of the aqueous and 332 
lipid phase. The data represents the mean ± SD (n=3).  333 
 334 
 335 
 336 
 337 
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4. Discussion 338 
The objective of this work was to assess the physicochemical properties of the NISV 339 
produced by three different methods. The TFH and heating methods have previously been 340 
reported to produce large multilamilar particles that require a post-manufacturing size 341 
reduction step [30], as confirmed by this study. Microfluidic mixing on the other hand was 342 
shown to produce small sized nanoparticles with low distribution in a single production 343 
step [24].  344 
Traditionally, the production of small and monodisperse particles using the TFH and 345 
heating methods were limited by the use of the post-manufacturing size reduction step to 346 
produce particles of the required size and to reduce the PDI. This has limited the use of 347 
these methods to bench scale since there is a much longer industrial scale process required 348 
to produce a consistently size end product. However, microfluidic mixing allows the 349 
production of controlled particle size with homogenous distribution in a single step without 350 
the need for post-manufacturing size reduction (Table 1). This offers the potential to 351 
facilitate the production of NISV at larger scale. Moreover, the production of these small 352 
particles by microfluidics can save time as the total preparation time took minutes while 353 
the production of small particles by the other methods required several hours. 354 
Next, we evaluated the stability of the vesicles over two months, at different storage 355 
temperatures following extended incubation by monitoring any changes in the particles 356 
size, PDI, and ZP. As can be seen in Figure 1, TFH and heating methods (post extrusion) 357 
and microfluidic mixing produced stable particles with respect to size with no significant 358 
change at all storage temperatures. Also, there was no significant change in the particles 359 
PDI and ZP at all the tested temperatures regardless of the method of preparation (data not 360 
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shown). Temperature can have an energy input to the system and can sometimes lead to 361 
changes in the crystalline structure of the lipids or might cause changes in the ZP and these 362 
changes might affect the stability of the particles [31]. Several researchers have reported 363 
the instability of the particles when stored at high temperatures. In two different studies, 364 
Feritas et al. (1998 and 1999) reported the instability of their solid lipid nanoparticles 365 
(SLN) with the introduction of energy to the system. This instability was reported in terms 366 
of size increase and reduction of ZP when the particles were stored at 50ºC [32, 33]. At 367 
4ºC, this was generally the most favourable storage condition although some reports 368 
indicate the instability of the formed particles when stored at low temperatures [31]. In this 369 
study, all three methods exhibited excellent stability at four different temperatures with no 370 
significant increase in the average particle size, PDI, and ZP (p>0.05) when stored for two 371 
months even at the higher storage temperatures. These data indicate that microfluidics not 372 
only enables rapid, robust, and scalable production of NISV, but also supports the stable 373 
formation of these vesicles which is necessary for applications requiring prolonged shelf 374 
life such as in pharmaceutical drug delivery. Although there was some residual ethanol in 375 
the formulations prepared by microfluidics, this good vesicles stability suggests that the 376 
amount of ethanol sequestered in the NISV bilayer is not significant as high ethanol content 377 
will promote rapid degradation of the bilayer structure which is not the case in these 378 
formulations. However, this residual ethanol can be removed, if necessary, via 379 
conventional batch purification techniques such as evaporation, extraction, or dialysis  380 
[34]. 381 
Morphological observations of AFM images confirmed the formation of spherical particles 382 
of NISV prepared by the TFH and heating methods after extrusion and by microfluidics 383 
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(Figure 2). These results confirmed that the particles prepared by microfluidics in a single 384 
step are similar to the extruded particles prepared by more traditional TFH and heating 385 
methods.  386 
Regarding the effects of the manufacturing methods on particle cytotoxicity, the viability 387 
of A375 and A2780 cells were measured after treatment with a range of NISV 388 
concentrations (9.76 -1250 µg/ml) prepared by all three methods. Cell metabolic activity 389 
measurements by conversion of resazurin showed no difference in cytotoxicity of the NISV 390 
prepared by the three methods as assessed by their EC50 values (Table 2). NISV with lipid 391 
concentrations below 150 µg/ml were non-toxic with 100% cell viability retained. Any 392 
difference in the physical characteristics of the particles such as size or charge would affect 393 
their cellular uptake, which would then affect cell viability [27, 35]. Here, since the 394 
particles prepared by the three methods have comparable characteristics in terms of size 395 
and charge, there was no difference on cell viability regardless of the method of 396 
preparation. This reflects the potential to have significant impact on various drug delivery 397 
applications by improving the manufacturing process of currently available NISV-based 398 
drugs. This would be achieved by replacing conventional methods of preparation with 399 
microfluidics to obtain the same outcomes, while gaining advantages in terms of rapid 400 
production of reproducible particles. 401 
For the formation of lipid-based particles through microfluidic mixing, the rate of mixing 402 
as well as the ratio of aqueous-to-solvent streams were anticipated to be crucial factors in 403 
particle preparation as these factors will affect the ratio of each phase in the mixing process 404 
as well as the mixing time between both phases [25, 36]. Therefore, NISV composed of 405 
MPG:Chol:DCP (5:4:1 molar ratio) were prepared by microfluidic mixing at different TFR 406 
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and FRR. The FRR strongly affected the final solvent concentration. At lower FRR (1:1), 407 
the final solvent concentration increased, thus boosting the production of larger particles 408 
due to particle fusion and lipid exchange while at higher FRR (5:1), the chance of 409 
producing large particles was reduced as a result of reduced solvent concentration. Previous 410 
work using hydrodynamic flow-focusing techniques for the preparation of NISV using 411 
different types of sorbitan esters surfactant have also been reported to increase NISV size 412 
with the decrease in FRR, which is in agreement with results in this study [23]. 413 
The effect of the TFR on particle size is still debatable. While some researchers have 414 
reported that TFR does not have a significant effect [37], others have reported the contrary 415 
[38]. In this study, TFR was shown to have an impact on particle size especially at values 416 
< 9 ml/min. This means that these two factors (FRR and TFR) should be optimised when 417 
NISV are formulated by microfluidic mixing. In our previous work, we have demonstrated 418 
that the aqueous media used also has a significant effect on NISV characteristics when 419 
prepared by microfluidics [27]. So microfluidic mixing allows the production of NISV with 420 
a tuned particle size by varying the TFR, FRR, and aqueous media. 421 
5. Conclusions 422 
In this work, the characteristics of NISV prepared by microfluidics were compared with 423 
those prepared by the conventional TFH and heating methods. Microfluidic mixing enabled 424 
preparation of small, monodisperse particles in a single step, without the need of a size 425 
reduction step as in the case of the other methods. The method of preparation did not have 426 
significant effects on particle stability and toxicity. Using microfluidic mixing, a 427 
homogenous NISV suspension was prepared with high reproducibility. FRR and TFR 428 
between the two phases of the microfluidic mixing are the factors that have significant 429 
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effects on particle characteristics, which can be optimised in order to produce NISV with 430 
a defined size which is important in developing an effective drug delivery system. This 431 
work suggests that the use of microfluidic mixing in NISV preparation may facilitate the 432 
development and optimisation of these dispersions for nanomedicine applications at both 433 
bench and industrial scales. 434 
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